Prostate cancer upgrade, downgrade rates in PI-RADS 2.0 versus 2.1

In line with a study revealed within the American Journal of Roentgenology (AJR)improve and downgrade charges from focused biopsy to radical prostatectomy weren’t considerably totally different between sufferers whose MRI examinations had been clinically interpreted utilizing PI-RADS Model v2.0 or v2.1.

“Implementation of the latest PI-RADS replace didn’t enhance the incongruence in prostate most cancers grade evaluation between focused biopsy and surgical procedure,” wrote corresponding writer Baris Turkbey, MD, from the Molecular Imaging Department of the Nationwide Most cancers Institute at Nationwide Institutes of Well being in Bethesda, MD.

Dr. Turkbey and colleagues’ AIR research entailed a retrospective post-hoc evaluation of sufferers who underwent 3-T prostate MRI at a single establishment from Might 2015 to March 2023 throughout potential scientific trials. From trial contributors, the authors recognized those that underwent MRI adopted by MRI/ultrasound-fusion guided focused biopsy and radical prostatectomy inside a 1-year interval. A single genitourinary radiologist carried out scientific interpretations of the MRI examinations utilizing PI-RADS v2.0 from Might 2015 to March 2019, and utilizing PI-RADS v2.1 from April 2019 to March 2023.

Finally, patients who underwent MRI interpreted by PI-RADS v2.0 and PI-RADS v2.1 confirmed no important variations in respective charges of improve (29% vs. 22%, p = .15), downgrade (19% vs. 21%, p = .76), clinically significant upgrade (14% vs. 10%, p = .27), or clinically important downgrade (1% vs. 1%, p>.99) from focused biopsy to radical prostatectomy grade group.